The Everbright Securities Research Report points out that Beijing, Guangzhou, Zhuhai and other places have successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to create a full-process service system to speed up the R&D to application process and optimize the pricing and payment settlement model for innovative pharmaceutical devices. Furthermore, when the ASCO conference is about to be held, a number of Chinese pharmaceutical companies announced that their interest in the new drug research and innovative drug market selected for this year's ASCO conference has increased.
光大证券研报指出北京、广州、珠海等地相继发布支持生物医药产业或创新药械高质量发展的相关政策打造全流程服务体系加快研发到应用进程优化创新药械的定价和支付结算模式。此外ASCO大会召开在即多家中国药企宣布了其入选本届ASCO大会的新药研究创新药市场关注度有所提升。
The Everbright Securities Research Report points out that Beijing, Guangzhou, Zhuhai and other places have successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to cre
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.